Rise Therapeutics LLC
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2017-01-01
- Employees
- 11
- Market Cap
- -
Clinical Trials
6
Active:0
Completed:0
Trial Phases
2 Phases
Phase 1:5
Not Applicable:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
Phase 1
5 (83.3%)Not Applicable
1 (16.7%)A Repeat Ascending Dosing Study of the Safety and Clinical Activity of R-3750 in Patients With Mild to Moderate COPD
Not Applicable
Not yet recruiting
- Conditions
- COPD (Chronic Obstructive Pulmonary Disease)COPD ExacerbationCOPD Exacerbation Acute
- Interventions
- First Posted Date
- 2025-07-22
- Last Posted Date
- 2025-07-22
- Lead Sponsor
- Rise Therapeutics LLC
- Target Recruit Count
- 27
- Registration Number
- NCT07076290
R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients With Solid Tumors
Phase 1
Recruiting
- Conditions
- Solid Tumor, AdultSolid TumorMelanomaBasal Cell CancerSquamous Cell CancerAdenoma
- Interventions
- First Posted Date
- 2024-05-03
- Last Posted Date
- 2025-09-04
- Lead Sponsor
- Rise Therapeutics LLC
- Target Recruit Count
- 33
- Registration Number
- NCT06398418
- Locations
- 🇺🇸
Sarah Cannon Research Institute, Nashville, Tennessee, United States
R-2487 in Patients With Sjogren's Syndrome (SS)
Phase 1
Not yet recruiting
- Conditions
- SjögrenSjogren's SyndromeSjögren Syndrome, Unspecified
- Interventions
- First Posted Date
- 2024-03-07
- Last Posted Date
- 2025-09-04
- Lead Sponsor
- Rise Therapeutics LLC
- Target Recruit Count
- 36
- Registration Number
- NCT06297213
R-5280 in Newly Diagnosed Patients with Type 1 Diabetes
Phase 1
Recruiting
- Conditions
- Type 1 DiabetesType 1 Diabetes (Juvenile Onset)Diabetes Mellitus, Type 1
- Interventions
- Other: Placebo
- First Posted Date
- 2023-09-28
- Last Posted Date
- 2025-03-24
- Lead Sponsor
- Rise Therapeutics LLC
- Target Recruit Count
- 39
- Registration Number
- NCT06057454
- Locations
- 🇺🇸
Edward Jenner Research Group LLC, Plantation, Florida, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
🇺🇸UTSW Medical Center, Dallas, Texas, United States
R-2487 in Patients With Rheumatoid Arthritis
Phase 1
Recruiting
- Conditions
- Arthritis, Rheumatoid
- Interventions
- Drug: R-2487 DP
- First Posted Date
- 2023-07-27
- Last Posted Date
- 2025-09-23
- Lead Sponsor
- Rise Therapeutics LLC
- Target Recruit Count
- 73
- Registration Number
- NCT05961592
- Locations
- 🇺🇸
University of California, San Diego, San Diego, California, United States
🇺🇸Prolato Clinical Research Center, Houston, Texas, United States
🇺🇸St.Jude Clinical Research, Doral, Florida, United States
- Prev
- 1
- 2
- Next
News
No news found